Brief: Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress

Caribou Biosciences

12/12/2022 14:32

Dec 12 (Reuters) - Caribou Biosciences Inc  CRBU.O :
    * CARIBOU BIOSCIENCES REPORTS CB-010 ANTLER PHASE 1 TRIAL
PROGRESS
    * CARIBOU BIOSCIENCES INC - LONG-TERM DURABILITY OBSERVED
FOR
CB-010 ALLOGENEIC CELL THERAPY AT DOSE LEVEL 1 IN ANTLER TRIAL
FOR R/R B-NHL
    * CARIBOU BIOSCIENCES INC - ANTLER TRIAL ENROLLING PATIENTS
AT
DOSE LEVEL 3

Source text for Eikon:  ID:nGNXbpvnzv 
Further company coverage:  CRBU.O 
 ((Reuters.Briefs@thomsonreuters.com;))